Skip to content
Screener

Acadia Pharmaceuticals ACAD Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Biogen logo
BiogenBIIB
$820.9M+2.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$260.9M+43.7%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$1.58M+31.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$2.09M-37.1%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$41.46M+26.1%

Other financials

Income statement

See full
Revenue$308.0M+16.4%
Gross profit$279.6M+14.7%
Operating income$37.8M+16.9%
Net income$31.5M+18.1%
EPS (diluted)$0.18+12.5%

Balance sheet

See full
Cash & equivalents$385.0M+51.8%
Total debt$73.9M+31.2%
Total equity$1.3B+58.9%
Total assets$1.7B+42.2%

Cash flow

See full
Operating cash flow$100.8M+57.6%
CapEx$5.1M+1,613%
Free cash flow$95.7M+50.3%

Valuation

See full
Market cap$4.9B+23.1%
Enterprise value$4.59B+21.3%
P/E12.9×-5.0×
P/S4.3×+0.4×

Profitability

See full
Gross margin91.1%-0.8pp
Operating margin7.6%-15.7pp
Net margin33.4%+11.6pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity35.7%+2.6pp
Debt / equity0.1×0.0×
Current ratio3.4×+0.5×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333243

FAQ

What is Acadia Pharmaceuticals's other non-current liabilities?
Acadia Pharmaceuticals (ACAD) reported other non-current liabilities of $15.31M in Q2 2026.
How has Acadia Pharmaceuticals's other non-current liabilities changed year-over-year?
Acadia Pharmaceuticals's other non-current liabilities decreased by 46.4% year-over-year, from $28.55M to $15.31M.
What is the long-term trend for Acadia Pharmaceuticals's other non-current liabilities?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's other non-current liabilities has grown at a 29.9% compound annual growth rate (CAGR), from $5.18M to $19.14M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Acadia Pharmaceuticals's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude